Tissue control of immunocytes

Research unit IMA-TCI studies the interaction of immunocytes with aberrant tissue cells in kidney liver and lung to provide new hypothesis for therapy improvement. Immune monitoring accompanying clinical trials shall identify new prognostic and predictive markers.

Click & View

About our research

The focus of our research are immunocytes in peripheral blood and within tissue where they have to be active to maintain health and fight disease. We study killer cells in cancer patients. They are detected even in patients with advanced disease, thus, their activity is obviously not sufficient to destroy the cancer cells. We wish to understand the immune suppression and explore strategies to better activate the patients' immune system. We use engineering approaches and means to change the tissue milieu to enable necessary immune reactivity. With our knowledge in flow cytometry and multiplex cytokine profiling we determine the features of those immunocytes, which can destroy the cancer cells. We work closely with clinicians and pharma, providing our knowledge for guidance to improve therapies and help patient selection for best therapeutic approach.

Topic 1

How an immune response is generated and controlled Understanding immune cell‘s phenotype, functional activity and communication (T cells, NK cells, and myeloid cells)

Topic 2

Immune cell engineering & immunotherapy

Engineering and activation for improved immunotherapy.

Chimeric switch protein (CSP) prevent inhibiting signal and turns it into stimulation.

This should increase T cell persistence and activity.

Topic 3

Tissue milieu

Tissue milieu factors and their influence on immunocytes

Topic 4

Immune monitoring & biomarker

Study-accompanying immune monitoring of tissue and peripheral blood for response-associated biomarker identification

Topic 5

Technologies & expertises

Flow cytometry, laser scanning microscopy, multiplex analysis, cytotoxicity assay, cell preparation, human blood cell activation assay.

Microscopy of tissue allows analyzing immunocytes in the milieu where they must be active to destroy pathogen or cancerous cells. Here we visualize T cells and macrophages in human cancer tissue and their interaction (in green a macrophage surrounded by T-cells in red).

Prof. Dr. Elfriede Nößner

Group Leader

Publications

2022 Meeting abstract in Journal of Clinical Oncology - JCO

Hofer, T.P. ; Nieto, A. ; Kaesmann, L. ; Taugner, J. ; Pelikan, C. ; Katanov, D. ; Eze, C. ; Guggenberger, J. ; Belka, C. ; Nößner, E. ; Manapov, F.

Absence of CD4(+) and CD8(+) T cell expansion after primary multimodal treatment predicts early progression in inoperable stage III NSCLC.

2022 Scientific Article in Cancers

Lyu, C. ; Wang, L. ; Stadlbauer, B. ; Nößner, E. ; Buchner, A. ; Pohla, H.

Identification of EZH2 as cancer stem cell marker in clear cell renal cell carcinoma and the anti-tumor effect of epigallocatechin-3-gallate (EGCG).

2022 Scientific Article in Cells

Brech, D. ; Herbstritt, A. ; Diederich, S. ; Straub, T. ; Kokolakis, E. ; Irmler, M. ; Beckers, J. ; Büttner, F.A. ; Schaeffeler, E. ; Winter, S. ; Nelson, P.J. ; Nößner, E.

Dendritic cells or macrophages? The microenvironment of human clear cell renal cell carcinoma imprints a mosaic myeloid subtype associated with patient survival.

2022 Scientific Article in JCI insight

Modak, M. ; Mattes, A.K. ; Reiss, D. ; Skronska-Wasek, W. ; Langlois, R. ; Sabarth, N. ; Konopitzky, R. ; Ramírez, F. ; Lehr, K. ; Mayr, T. ; Kind, D. ; Viollet, C. ; Swee, L.K. ; Petschenka, J. ; El Kasmi, K.C. ; Nößner, E. ; Kitt, K. ; Pflanz, S.

CD206+ tumor-associated macrophages cross-present tumor antigen and drive anti-tumor immunity.

2022 Scientific Article in Cancers

Sailer, N. ; Fetzer, I. ; Salvermoser, M. ; Braun, M. ; Brechtefeld, D. ; Krendl, C. ; Geiger, C. ; Mutze, K. ; Nößner, E. ; Schendel, D.J. ; Bürdek, M. ; Wilde, S. ; Sommermeyer, D.

T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity.

2022 Scientific Article in Translational Lung Cancer Research

Käsmann, L. ; Taugner, J. ; Eze, C. ; Nieto, A. ; Pelikan, C. ; Floersch, B. ; Kenndoff, S. ; Hofer, T.P. ; Nößner, E. ; Schulz, C. ; Unterrainer, M. ; Tufman, A. ; Klauschen, F. ; Jung, A. ; Neumann, J. ; Kumbrink, J. ; Reinmuth, N. ; Bartenstein, P. ; Belka, C. ; Manapov, F.

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): Protocol for a prospective longitudinal biomarker study.

2021 Scientific Article in Frontiers in Immunology

Grunewald, C.M. ; Haist, C. ; König, C. ; Petzsch, P. ; Bister, A. ; Nößner, E. ; Wiek, C. ; Scheckenbach, K. ; Köhrer, K. ; Niegisch, G. ; Hanenberg, H. ; Hoffmann, M.J.

Epigenetic priming of bladder cancer cells with decitabine increases cytotoxicity of human EGFR and CD44v6 CAR engineered T-cells.

2021 Review in Cancers

Mancini, M. ; Righetto, M. ; Nößner, E.

Checkpoint inhibition in bladder cancer: Clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach.

2021 Scientific Article in Frontiers in Immunology

Olguín-Contreras, L.F. ; Mendler, A.N. ; Popowicz, G.M. ; Hu, B. ; Nößner, E.

Double strike approach for tumor attack: Engineering T cells using a CD40L:CD28 chimeric co-stimulatory switch protein for enhanced tumor targeting in adoptive cell therapy.

2021 Scientific Article in Journal of Reproductive Immunology

Schmitz, T. ; Hoffmann, V. ; Olliges, E. ; Bobinger, A. ; Popovici, R. ; Nößner, E. ; Meissner, K.

Reduced frequency of perforin-positive CD8+ T cells in menstrual effluent of endometriosis patients.

2021 Scientific Article in European Journal of Cancer

Issels, R.D. ; Nößner, E. ; Lindner, L.H. ; Schmidt, M. ; Albertsmeier, M. ; Blay, J.Y. ; Stutz, E. ; Xu, Y. ; Buecklein, V. ; Altendorf-Hofmann, A. ; Abdel-Rahman, S. ; Mansmann, U. ; von Bergwelt-Baildon, M. ; Knoesel, T.

Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.

2021 Scientific Article in Frontiers in Immunology

Chu, C.F. ; Sabath, F. ; Fibi-Smetana, S. ; Sun, S. ; Öllinger, R. ; Nößner, E. ; Chao, Y.Y. ; Rinke, L.L. ; Winheim, E. ; Rad, R. ; Krug, A.B. ; Taher, L. ; Zielinski, C.E.

Convalescent COVID-19 patients without comorbidities display similar immunophenotypes over time despite divergent disease severities.

2021 Scientific Article in Journal of Hepatology

Quitt, O. ; Luo, S. ; Meyer, M. ; Xie, Z. ; Golsaz-Shirazi, F. ; Loffredo-Verde, E. ; Festag, J. ; Bockmann, J.H. ; Zhao, L. ; Stadler, D. ; Chou, W.M. ; Tedjokusumo, R. ; Wettengel, J.M. ; Ko, C. ; Nößner, E. ; Bulbuc, N. ; Shokri, F. ; Lüttgau, S. ; Heikenwälder, M. ; Bohne, F. ; Moldenhauer, G. ; Momburg, F. ; Protzer, U.

T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.

2021 Scientific Article in Frontiers in Immunology

Holmen Olofsson, G. ; Idorn, M. ; Carnaz Simões, A.M. ; Aehnlich, P. ; Skadborg, S.K. ; Nößner, E. ; Debets, R. ; Moser, B. ; Met, Ö. ; Thor Straten, P.

Vγ9Vδ2 T cells concurrently kill cancer cells and cross-present tumor antigens.

2021 Scientific Article in Scientific Reports

Esteve-Codina, A. ; Hofer, T.P. ; Burggraf, D. ; Heiss-Neumann, M.S. ; Gesierich, W. ; Boland, A. ; Olaso, R. ; Bihoreau, M.T. ; Deleuze, J.F. ; Möller, W. ; Schmid, O. ; Soler Artigas, M. ; Renner, K. ; Hohlfeld, J.M. ; Welte, T. ; Fuehner, T. ; Jerrentrup, L. ; Koczulla, A.R. ; Greulich, T. ; Prasse, A. ; Müller-Quernheim, J. ; Gupta, S. ; Brightling, C. ; Subramanian, D.R. ; Parr, D.G. ; Kolsum, U. ; Gupta, V. ; Barta, I. ; Döme, B. ; Strausz, J. ; Stendardo, M. ; Piattella, M. ; Boschetto, P. ; Korzybski, D. ; Gorecka, D. ; Nowinski, A. ; Dabad, M. ; Fernández-Callejo, M. ; Endesfelder, D. ; zu Castell, W. ; Hiemstra, P.S. ; Venge, P. ; Nößner, E. ; Griebel, T. ; Heath, S. ; Singh, D. ; Gut, I. ; Ziegler-Heitbrock, L.

Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes.

2021 Scientific Article in Human Gene Therapy. Clinical Development

Dudaniec, K. ; Westendorf, K. ; Nößner, E. ; Uckert, W.

Nößner Lab

Click & View

About our research

Our Research Topics

Topic 1

Topic 2

Topic 3

Topic 4

Topic 5

Our scientists at Nößner Lab

Prof. Dr. Elfriede Nößner

Publications

Absence of CD4(+) and CD8(+) T cell expansion after primary multimodal treatment predicts early progression in inoperable stage III NSCLC.

Identification of EZH2 as cancer stem cell marker in clear cell renal cell carcinoma and the anti-tumor effect of epigallocatechin-3-gallate (EGCG).

Dendritic cells or macrophages? The microenvironment of human clear cell renal cell carcinoma imprints a mosaic myeloid subtype associated with patient survival.

CD206+ tumor-associated macrophages cross-present tumor antigen and drive anti-tumor immunity.

T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity.

Epigenetic priming of bladder cancer cells with decitabine increases cytotoxicity of human EGFR and CD44v6 CAR engineered T-cells.

Checkpoint inhibition in bladder cancer: Clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach.

Double strike approach for tumor attack: Engineering T cells using a CD40L:CD28 chimeric co-stimulatory switch protein for enhanced tumor targeting in adoptive cell therapy.

Reduced frequency of perforin-positive CD8+ T cells in menstrual effluent of endometriosis patients.

Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.

Convalescent COVID-19 patients without comorbidities display similar immunophenotypes over time despite divergent disease severities.

T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.

Vγ9Vδ2 T cells concurrently kill cancer cells and cross-present tumor antigens.

Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes.

Generation of Epstein-Barr virus antigen-specific T cell receptors recognizing immunodominant epitopes of LMP1, LMP2A, and EBNA3C for immunotherapy.

Contact

Prof. Dr. Elfriede Nößner

Privacy settings